Oculis Holding AG
OCS
Positions held
Your positionsOCS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $533.35M | Enterprise value | $308.82M | Trailing P/E | — | Forward P/E | -4.38 |
| PEG | — | Price / book | 2.01 | Beta | 0.27 | Dividend yield | 0.00% |
| Revenue growth | 18.8% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -76.0% |
| Profit margin | 0.0% | ROE | -43.7% | ROA | -25.0% | Debt / equity | 0.01 |
| Current ratio | 8.35 | Free cash flow | -$41.37M | Analyst recommendation | strong_buy | Mean target | $36.58 |
| 52w high | $34.48 | 52w low | $8.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$10.0M | -$28.9M | -$23.5M | -$16.9M | -$25.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.6M | -$21.7M | -$20.6M | -$20.3M | -$20.8M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$99.0M | -$85.8M | -$88.8M | -$38.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$81.7M | -$73.2M | -$45.9M | -$32.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-10-07 · Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
2026-10-07 · Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
2026-10-01 · Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
2026-10-01 · Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
2026-09-30 · Oculis Announces Resignation of Lionel Carnot from Board of Directors
2026-09-30 · Oculis Announces Resignation of Lionel Carnot from Board of Directors
2026-09-28 · After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
2026-09-23 · Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
2026-09-17 · Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-08-31 · Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
2026-08-24 · Oculis Treats First Patient in Optic Neuritis Trial; Shares Up Pre-Bell
Price (daily)
Full chart · RSI · MACD · patterns